Data gathered: April 15
AI Stock Analysis - Esperion Therapeutics (ESPR)
Analysis generated March 14, 2025. Powered by Chat GPT.
Esperion Therapeutics, a biopharmaceutical company focused on discovering and developing novel therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C), exhibits both promise and challenge. The company's primary product candidate, bempedoic acid, is pioneering progress in cholesterol management. However, industry competition, regulatory hurdles, and internal metrics will significantly influence Esperion's investment viability.
Stock Alerts - Esperion Therapeutics (ESPR)
 |
Esperion Therapeutics | April 10 Price is down by -5.1% in the last 24h. |
|
Esperion Therapeutics | April 9 Price is down by -5.2% in the last 24h. |
|
Esperion Therapeutics | April 8 Price is down by -5.8% in the last 24h. |
|
Esperion Therapeutics | April 8 Employee Rating is down by 2.9% over the last month. |
Alternative Data for Esperion Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 14 | Sign up | Sign up | Sign up |
| Sentiment | 82 | Sign up | Sign up | Sign up |
| Webpage traffic | 50,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 7 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1,043 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 9,001 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,089 | Sign up | Sign up | Sign up |
| Twitter Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 56 | Sign up | Sign up | Sign up |
| Linkedin Employees | 339 | Sign up | Sign up | Sign up |
About Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
| Price | $1.00 |
| Target Price | Sign up |
| Volume | 7,050,000 |
| Market Cap | $202M |
| Year Range | $0.96 - $3.83 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Drug Manufacturers |
In the news
 |
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?April 3 - Yahoo |
 |
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of “Moderate Buy” by BrokeragesApril 1 - ETF Daily News |
|
Cibc World Markets Corp Takes $39,000 Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)March 29 - ETF Daily News |
|
Brokers Set Expectations for ESPR FY2027 EarningsMarch 28 - ETF Daily News |
|
Zacks Research Brokers Decrease Earnings Estimates for ESPRMarch 28 - ETF Daily News |
 |
Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC WainwrightMarch 23 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 52M | 40M | 12M | -30M | -14M | -0.150 |
| Q2 '24 | 21M | 44M | -24M | -62M | -48M | -0.330 |
| Q1 '24 | 124M | 42M | 82M | 61M | 75M | 0.340 |
| Q4 '23 | 17M | 45M | -28M | -56M | -41M | -0.500 |
| Q3 '23 | 19M | 33M | -14M | -41M | -28M | -0.370 |
Insider Transactions View All
| Warren Eric filed to sell 370,326 shares at $1.5. March 19 '25 |
| Halladay Benjamin filed to sell 481,710 shares at $1.5. March 19 '25 |
| Koenig Sheldon L. filed to sell 1,571,962 shares at $1.5. March 19 '25 |
| Halladay Benjamin filed to sell 240,671 shares at $1.9. February 20 '25 |
| Warren Eric filed to sell 159,759 shares at $1.9. February 20 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$154.36 0% | 50 |
 |
Eli Lilly and CompanyLLY |
$754.35 0% | 69 |
 |
PfizerPFE |
$22.12 0% | 32 |
 |
AstrazenecaAZN |
$68.01 0% | 42 |
 |
AbbVieABBV |
$179.1 0% | 35 |
Read more about Esperion Therapeutics (ESPR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Esperion Therapeutics?
The Market Cap of Esperion Therapeutics is $202M.
What is the current stock price of Esperion Therapeutics?
Currently, the price of one share of Esperion Therapeutics stock is $1.00.
How can I analyze the ESPR stock price chart for investment decisions?
The ESPR stock price chart above provides a comprehensive visual representation of Esperion Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Esperion Therapeutics shares. Our platform offers an up-to-date ESPR stock price chart, along with technical data analysis and alternative data insights.
Does ESPR offer dividends to its shareholders?
As of our latest update, Esperion Therapeutics (ESPR) does not offer dividends to its shareholders. Investors interested in Esperion Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Esperion Therapeutics?
Some of the similar stocks of Esperion Therapeutics are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.